Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction
Selective serotonin reuptake inhibitors (SSRIs) are a standard of care for the pharmacotherapy of patients suffering from Major Depressive Disorder (MDD). However, only one-half to two-thirds of MDD patients respond to SSRI therapy. Recently, a “multiple omics” research strategy was applied to ident...
Main Authors: | Thanh Thanh L. Nguyen, Duan Liu, Ming-Fen Ho, Arjun P. Athreya, Richard Weinshilboum |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.614048/full |
Similar Items
-
Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine
by: Charalabos Antonatos, et al.
Published: (2023-04-01) -
Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
by: Azmeraw T. Amare, et al.
Published: (2018-03-01) -
Review of sexual dysfunction due to selective serotonin reuptake inhibitors
by: P Srilakshmi, et al.
Published: (2012-01-01) -
A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials
by: Zhong Z, et al.
Published: (2017-11-01) -
New Serotonin-Norepinephrine Reuptake Inhibitors and Their Anesthetic and Analgesic Considerations
by: David Fanelli, et al.
Published: (2021-10-01)